HIV Transmission Risk: High-Risk Behaviors & Populations

HIV transmission requires sufficient viral load in body fluids (blood, semen, vaginal/rectal fluids, breast milk) and a portal of entry (mucosa, broken skin, direct bloodstream). Risk varies enormously by behavior and population.

Highest Risk Behaviors (Per-Act Probability)

  • Receptive Anal Intercourse: ~1.4% (highest sexual risk) — large surface area, thin mucosa, high target cell density.
  • Insertive Anal Intercourse: ~0.1%.
  • Receptive Vaginal Intercourse: ~0.08%.
  • Insertive Vaginal Intercourse: ~0.04%.
  • Sharing Injection Equipment: ~0.6% per act (needles, syringes, cookers, cotton, water) — direct blood exposure.
  • Mother-to-Child (without ART): 15–45% (pregnancy, delivery, breastfeeding). With ART (viral suppression): <1%.

Elevated Risk Populations (U.S. Epidemiology)

  • Men who have sex with men (MSM): 67% of new diagnoses; biological (anal sex efficiency) + network factors.
  • People who inject drugs (PWID): 7% of diagnoses; sharing equipment + sexual risk.
  • Transgender women: Disproportionate burden (estimated 14% prevalence).
  • Black/African American & Hispanic/Latino communities: Higher prevalence due to structural factors (access, stigma, network prevalence), not individual behavior alone.
  • Sex workers & clients.
  • Incarcerated populations.
  • Serodiscordant couples.
  • Individuals with other STIs: Ulcerative (HSV, syphilis) or inflammatory (chlamydia, gonorrhea) disrupt mucosa, ↑ target cells.
  • People with TB: Immune activation, overlapping risk factors.

Lower Risk (But Not Zero)

  • Oral sex (very low; case reports exist, mostly receptive fellatio with ejaculation).
  • Blood transfusion/organ transplant (extremely rare with nucleic acid testing).
  • Occupational needlestick (~0.3% per exposure).

Prevention Toolkit (Combination Prevention)

  • Consistent condom use (external/internal).
  • PrEP (Pre-Exposure Prophylaxis): TDF/FTC or TAF/FTC daily, or event-driven (2-1-1) for MSM; >99% effective when adherent. Cabotegravir LA (injectable q2mo) approved.
  • PEP (Post-Exposure Prophylaxis): Start ≤72h (ideally ≤24h), 28-day course.
  • Treatment as Prevention (TasP): Undetectable = Untransmittable (U=U). Viral suppression eliminates sexual transmission.
  • Syringe service programs, opioid agonist therapy (methadone, buprenorphine).
  • Routine opt-out screening per CDC (ages 13–64 at least once; high-risk annually).

Risk is modifiable. Tailored, combination prevention saves lives.

HIV & AIDS - Related Articles